America’s obesity crisis meets the Ozempic boom as data reveals GLP-1 hot spots
Insurance data reveals dramatic regional differences in Ozempic and Mounjaro usage, with obesity-heavy states prescribing GLP-1 medications at triple the rate of others.
Insurance data reveals dramatic regional differences in Ozempic and Mounjaro usage, with obesity-heavy states prescribing GLP-1 medications at triple the rate of others.
Read the full article at:
Fox News →